Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
20 hedge funds and large institutions have $4.76M invested in Evoke Pharma in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 7 closing their positions.
0.03% less ownership
Funds ownership: 0.13% → 0.1% (-0.03%)
26% less funds holding
Funds holding: 27 → 20 (-7)
26% less capital invested
Capital invested by funds: $6.45M → $4.76M (-$1.69M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$34.2K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$9.21K |
| 3 |
BlackRock
New York
|
+$1.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$857K |
| 2 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$249K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58K |
| 4 |
VF
Virtu Financial
New York
|
-$48K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| – | -$26K | -81 | Closed |
|
EVOK Hedge Fund Activity: Q1 2018 in Review
20 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2018, worth a combined $4.76M — down 26% from $6.45M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVOK and 0 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was PNC Financial Services Group, adding an estimated $34.2K. The largest seller was Sphera Funds Management, cutting an estimated $857K.
- 20 institutional investors held Evoke Pharma (EVOK) as of Q1 2018, down from 27 in Q4 2017.
- Funds reported $4.76M of Evoke Pharma stock for Q1 2018, down 26% quarter-over-quarter.
- 0 funds opened new Evoke Pharma positions in Q1 2018 and 7 closed out, a net change of -7 holders.
- The largest Evoke Pharma buyer in Q1 2018 was PNC Financial Services Group, an estimated $34.2K added.
- The largest Evoke Pharma seller in Q1 2018 was Sphera Funds Management, an estimated $857K sold.
Based on aggregated 13F filings for Q1 2018.